ZyVersa Therapeutics, Inc. (ZVSA): auditor change — ZyVersa Therapeutics replaces auditor Marcum LLP with CBIZ CPAs; notes material weaknesses and going concern

ZyVersa Therapeutics, Inc.

Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.
Marcum's reports for FY2023 and FY2024 included an explanatory paragraph about substantial doubt on the company's ability to continue as a going concern.
Company disclosed material weaknesses in internal control over financial reporting for both FY2023 and FY2024, including lack of segregation of duties.
No disagreements on accounting principles occurred between the company and Marcum during the relevant periods.
Marcum furnished a letter agreeing with the statements; filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Marcum LLP resigned as auditor of ZyVersa Therapeutics, Inc..

Action: resignation
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 4, 2025, Marcum resigned as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ZyVersa Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

with the approval of the Audit Committee of the Company’s Board of Directors, the Company engaged CBIZ CPAs as the Company’s independent registered public accounting firm, effective as of April 7, 2025

View on SEC.gov

Browse all auditor changes →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-003034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.